Mainz Biomed (NASDAQ:MYNZ – Free Report) had its target price reduced by HC Wainwright from $9.00 to $5.00 in a report issued on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2023 earnings at ($0.31) EPS, FY2023 earnings at ($1.67) […]